NASDAQ:GNCAGenocea Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genocea Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.75 +0.03 (+1.10 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$2.60Now: $2.75▼$2.7850-Day Range$1.81MA: $2.77▼$5.5352-Week Range$1.10Now: $2.75▼$5.75Volume439,727 shsAverage Volume627,705 shsMarket Capitalization$82.40 millionP/E RatioN/ADividend YieldN/ABeta2.42 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingGenocea Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Genocea Biosciences has a potential upside of 154.5% from its current price of $2.75.Amount of Analyst CoverageGenocea Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesGenocea Biosciences has received 379 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenocea Biosciences has received 298 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenocea Biosciences has received 55.98% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote “Outperform” if you believe GNCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenocea Biosciences does not currently pay a dividend.Dividend GrowthGenocea Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genocea Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,090,335.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.08% of the stock of Genocea Biosciences is held by insiders.Percentage Held by Institutions50.20% of the stock of Genocea Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Genocea Biosciences are expected to grow in the coming year, from ($1.21) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genocea Biosciences is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genocea Biosciences is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenocea Biosciences has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.19 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNCA Previous Symbol CUSIPN/A CIK1457612 Webwww.genocea.com Phone617-876-8191Debt Debt-to-Equity Ratio1.29 Current Ratio1.15 Quick Ratio1.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book3.09Profitability EPS (Most Recent Fiscal Year)($2.09) Net Income$-38,950,000.00 Net MarginsN/A Return on Equity-219.99% Return on Assets-83.12%Miscellaneous Employees61 Outstanding Shares29,964,000Market Cap$82.40 million Next Earnings Date10/22/2020 (Estimated) OptionableOptionable $2.75 +0.03 (+1.10 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GNCA News and Ratings via Email Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter. Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions How has Genocea Biosciences' stock price been impacted by Coronavirus? Genocea Biosciences' stock was trading at $1.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GNCA shares have increased by 50.3% and is now trading at $2.75. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Genocea Biosciences? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Genocea Biosciences. When is Genocea Biosciences' next earnings date? Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020. View our earnings forecast for Genocea Biosciences. How were Genocea Biosciences' earnings last quarter? Genocea Biosciences Inc (NASDAQ:GNCA) announced its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.01. The biotechnology company had revenue of $0.91 million for the quarter. View Genocea Biosciences' earnings history. What price target have analysts set for GNCA? 3 brokerages have issued 1-year price targets for Genocea Biosciences' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Genocea Biosciences' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 154.5% from the stock's current price. View analysts' price targets for Genocea Biosciences. Has Genocea Biosciences been receiving favorable news coverage? News articles about GNCA stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Genocea Biosciences earned a daily sentiment score of 0.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Genocea Biosciences. Are investors shorting Genocea Biosciences? Genocea Biosciences saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 231,500 shares, an increase of 161.9% from the June 15th total of 88,400 shares. Based on an average daily volume of 391,300 shares, the days-to-cover ratio is currently 0.6 days. Approximately 1.4% of the shares of the company are sold short. View Genocea Biosciences' Short Interest. Who are some of Genocea Biosciences' key competitors? Some companies that are related to Genocea Biosciences include Eiger Biopharmaceuticals (EIGR), Harpoon Therapeutics (HARP), Cabaletta Bio (CABA), ADMA Biologics (ADMA), DBV TECHNOLOGIE/S (DBVT), Dyadic International (DYAI), CASI Pharmaceuticals (CASI), Fennec Pharmaceuticals (FENC), Pluristem Therapeutics (PSTI), LogicBio Therapeutics (LOGC), Sutro Biopharma (STRO), GENFIT S A/ADR (GNFT), Axcella Health (AXLA), Surface Oncology (SURF) and Jounce Therapeutics (JNCE). View all competitors. What other stocks do shareholders of Genocea Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO). Who are Genocea Biosciences' key executives? Genocea Biosciences' management team includes the following people: Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55) What is Genocea Biosciences' stock symbol? Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA." Who are Genocea Biosciences' major shareholders? Genocea Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (6.74%), Wedbush Securities Inc. (0.16%), Virtu Financial LLC (0.12%) and WINTON GROUP Ltd (0.10%). Company insiders that own Genocea Biosciences stock include George Siber, Michael Alfieri, Paul Edward Walker and Peter W Sonsini. View institutional ownership trends for Genocea Biosciences. Which major investors are selling Genocea Biosciences stock? GNCA stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL. View insider buying and selling activity for Genocea Biosciences. Which major investors are buying Genocea Biosciences stock? GNCA stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Virtu Financial LLC, and WINTON GROUP Ltd. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri, Paul Edward Walker, and Peter W Sonsini. View insider buying and selling activity for Genocea Biosciences. How do I buy shares of Genocea Biosciences? Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Genocea Biosciences' stock price today? One share of GNCA stock can currently be purchased for approximately $2.75. How big of a company is Genocea Biosciences? Genocea Biosciences has a market capitalization of $82.40 million. The biotechnology company earns $-38,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe. What is Genocea Biosciences' official website? The official website for Genocea Biosciences is www.genocea.com. How can I contact Genocea Biosciences? Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected] This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
